Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03728335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03728335 · ClinicalTrials.gov record · last posted 2026-08-21

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Name: Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation — clinical trial record (NCT03728335)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusSuspended

PhasePhase 2

SponsorCity of Hope Medical Center

Started2019-12-23

View on ClinicalTrials.gov ↗

Why the trial stopped

Accrual goal met

from the ClinicalTrials.gov record

This phase II trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Protocol amendment history 2 changes detected by DataLookout

2026-08-22

Recruitment suspended

2026-08-22

Recruitment suspended: Accrual goal met

Trial Details

NCT Number	NCT03728335
Lead Sponsor	City of Hope Medical Center Collaborators: National Cancer Institute (NCI)
Conditions	Acute Myeloid Leukemia
Enrollment	35 participants
Start Date	2019-12-23
Primary Completion	2027-01-11 (estimated)
Study Completion	2027-01-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-21